Genomic Health, Inc. (GHDX) Given Average Rating of “Hold” by Analysts

Shares of Genomic Health, Inc. (NASDAQ:GHDX) have been assigned an average rating of “Hold” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation, one has given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $34.22.

A number of brokerages have recently commented on GHDX. LADENBURG THALM/SH SH lowered shares of Genomic Health from a “buy” rating to a “neutral” rating and set a $33.00 price target on the stock. in a report on Wednesday, June 13th. ValuEngine upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 7th. Canaccord Genuity boosted their target price on shares of Genomic Health from $41.00 to $45.00 and gave the company a “buy” rating in a report on Monday, June 4th. BidaskClub upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 12th. Finally, Zacks Investment Research upgraded shares of Genomic Health from a “hold” rating to a “strong-buy” rating and set a $42.00 target price on the stock in a report on Wednesday, May 9th.

In other news, insider Kimberly J. Popovits sold 15,000 shares of the company’s stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $33.19, for a total transaction of $497,850.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Steven Shak sold 5,500 shares of the company’s stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $50.22, for a total transaction of $276,210.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 140,911 shares of company stock worth $6,170,525. 45.80% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Emory University raised its holdings in shares of Genomic Health by 17.8% during the fourth quarter. Emory University now owns 62,926 shares of the medical research company’s stock valued at $2,152,000 after purchasing an additional 9,487 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Genomic Health by 16.2% during the fourth quarter. Renaissance Technologies LLC now owns 1,012,000 shares of the medical research company’s stock valued at $34,610,000 after purchasing an additional 141,300 shares during the period. University of Notre Dame DU Lac raised its holdings in shares of Genomic Health by 11.8% during the fourth quarter. University of Notre Dame DU Lac now owns 92,279 shares of the medical research company’s stock valued at $3,156,000 after purchasing an additional 9,776 shares during the period. York Capital Management Global Advisors LLC acquired a new position in shares of Genomic Health during the fourth quarter valued at about $423,000. Finally, Trexquant Investment LP acquired a new position in shares of Genomic Health during the first quarter valued at about $551,000. Hedge funds and other institutional investors own 89.77% of the company’s stock.

Shares of Genomic Health opened at $51.38 on Friday, Marketbeat Ratings reports. The firm has a market cap of $1.77 billion, a PE ratio of 5,138.00 and a beta of 0.64. Genomic Health has a 52 week low of $26.54 and a 52 week high of $53.65.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.08. The company had revenue of $92.60 million for the quarter, compared to analyst estimates of $88.95 million. Genomic Health had a negative net margin of 1.95% and a positive return on equity of 3.15%. Genomic Health’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.02) earnings per share. research analysts forecast that Genomic Health will post 0.47 EPS for the current year.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply